Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences

 
• By Joseph Haas

Merck adds to its stagnating HIV portfolio with US approvals of doravirine and a three-drug combo including the NNRTI, but the combo’s potential may be limited due to inclusion of an older version of tenofovir.

Form close up, fountain pen and approved stamped on a document. Soft focus.

More from New Products

More from Scrip